Sunesis Pharmaceuticals, Inc. to Host Analyst & Institutional Investor Meeting on October 4, 2012

SOUTH SAN FRANCISCO, Calif., Sept. 27, 2012 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the Company will host an analyst and institutional investor meeting on Thursday, October 4, 2012, from 5:00 to 6:30 PM Eastern Time in New York City. The event will include an overview of vosaroxin and the VALOR trial, a pivotal Phase 3, randomized, controlled, double-blind, multinational clinical trial in first relapsed or refractory acute myeloid leukemia (AML), as well as the Less Intensive 1 (LI-1) Study being conducted by the United Kingdom's National Cancer Research Institute (NCRI) Haematological Oncology Study Group.

Back to news